Search Results

Displaying Results 101-106 of 106 "'TME'"

Oct 14, 2025, 02:19 ET Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting

which can attract CTL to infiltrate into the TME, and activate CTLs and reduce CTL exhaustion. At the same time, it can also reduce the attraction of immunosuppressive cells (such as: TAM, Treg, and MDSCs) into the TME, so as to achieve the remodeling of the TME, which is more conducive to obtaining the

More news about: Great Novel Therapeutics Biotech & Medicals Corporation


Oct 13, 2025, 08:30 ET IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

now that ProSense® has received the FDA's marketing authorization in the U.S. for low-risk breast cancer in the days following the TME Summit." The TME summit focused on the evolving paradigm of de-escalation strategies in early and high-risk breast cancer care, with special emphasis

More news about: IceCure Medical


Sep 24, 2025, 07:00 ET Pathios Therapeutics Appoints Jon Wigginton, M.D., as Non-Executive Director

is exclusively expressed on immune cells and is associated with driving the immunosuppressive immune cell phenotype in the tumour microenvironment (TME) that prevents immune-mediated killing of cancer cells. Antagonism of GPR65 has been shown to rapidly upregulate anti-tumour natural killer and T cell

More news about: Pathios Therapeutics


Sep 23, 2025, 06:00 ET Tencent Music Entertainment Group Announces New Audit Committee Member

Sept. 23, 2025 /PRNewswire/ -- Tencent Music Entertainment Group ("TME", or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced

More news about: Tencent Music Entertainment Group


Sep 18, 2025, 17:31 ET NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight

& Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, among others.

More news about: DelveInsight Business Research, LLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.